Natural Product (NP) Details
General Information of the NP (ID: NP3615) | |||||
---|---|---|---|---|---|
Name |
Piceatannol
|
||||
Synonyms |
piceatannol; 10083-24-6; 3-Hydroxyresveratol; piceatanol; astringinin; 3,5,3',4'-Tetrahydroxystilbene; (E)-4-(3,5-dihydroxystyryl)benzene-1,2-diol; 3,3',4'5-Tetrahydroxystilbene; 4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,2-diol; 3,3',4,5'-Tetrahydroxystilbene; UNII-6KS3LS0D4F; NSC 365798; NSC-365798; NSC 622471; 6KS3LS0D4F; CHEMBL69863; 3,3',4,5'-Stilbenetetrol; 4-[(E)-2-(3,5-dihydroxyphenyl)vinyl]benzene-1,2-diol; 4339-71-3; CHEBI:28814; C14H12O4; NSC365798; NSC622471; 1,2-Benzenediol, 4-(2-(3,5-dihydroxyphenyl)ethenyl)-
Click to Show/Hide
|
||||
Species Origin | Rhodomyrtus tomentosa ... | Click to Show/Hide | |||
Rhodomyrtus tomentosa | |||||
Disease | Cytomegalovirus infection [ICD-11: 1A24] | Investigative | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C14H12O4
|
||||
PubChem CID | |||||
Canonical SMILES |
C1=CC(=C(C=C1C=CC2=CC(=CC(=C2)O)O)O)O
|
||||
InChI |
1S/C14H12O4/c15-11-5-10(6-12(16)8-11)2-1-9-3-4-13(17)14(18)7-9/h1-8,15-18H/b2-1+
|
||||
InChIKey |
CDRPUGZCRXZLFL-OWOJBTEDSA-N
|
||||
CAS Number |
CAS 10083-24-6
|
||||
ChEBI ID | |||||
Herb ID | |||||
ETMC ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Gemcitabine | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Augmenting Drug Sensitivity | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Up-regulation | Expression | BAK | Molecule Info |
Pathway MAP
|
|
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
Piceatannol can enhance the cytotoxic effects of gemcitabine by enhancing expression of the proapoptotic protein Bak. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Interferon regulatory factor 3 (IRF3) | Molecule Info | [3] | |
KEGG Pathway | Toll-like receptor signaling pathway | Click to Show/Hide | ||
2 | RIG-I-like receptor signaling pathway | |||
3 | Cytosolic DNA-sensing pathway | |||
4 | Pertussis | |||
5 | Hepatitis C | |||
6 | Hepatitis B | |||
7 | Measles | |||
8 | Influenza A | |||
9 | Herpes simplex infection | |||
10 | Epstein-Barr virus infection | |||
11 | Viral carcinogenesis | |||
Panther Pathway | Toll receptor signaling pathway | Click to Show/Hide | ||
Reactome | ISG15 antiviral mechanism | Click to Show/Hide | ||
2 | LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | |||
3 | Interferon gamma signaling | |||
4 | Interferon alpha/beta signaling | |||
5 | TRAF3-dependent IRF activation pathway | |||
6 | TRAF6 mediated IRF7 activation | |||
7 | Negative regulators of RIG-I/MDA5 signaling | |||
8 | Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | |||
9 | Factors involved in megakaryocyte development and platelet production | |||
WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
2 | Cytosolic sensors of pathogen-associated DNA | |||
3 | MyD88-independent cascade | |||
4 | ISG15 antiviral mechanism | |||
5 | Apoptosis | |||
6 | RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways | |||
7 | Factors involved in megakaryocyte development and platelet production | |||
8 | Regulation of toll-like receptor signaling pathway |
